Progress and Recent Developments in HIV Vaccine Research.

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Human immunodeficiency virus (HIV) remains a global health concern.
• Developing an effective HIV vaccine is challenging due to the virus's genetic variability and mutation rate.
• Antiretroviral therapy and prevention strategies have advanced, but a vaccine is crucial.

Purpose of the Study:

• To comprehensively review HIV vaccine candidates and clinical trial progress from the late 1990s to 2025.
• To trace the evolution of HIV vaccine strategies.
• To synthesize findings from Phase 1-3 trials.

Main Methods:

• Searched PubMed and ClinicalTrials.gov for English-language HIV vaccine trials (Phase 1-3).
• Screened titles, abstracts, and full texts for relevant trials published from 1990 to March 2025.
• Extracted data on trial phase, regimen, immunogenicity, efficacy, and correlates; synthesized findings narratively.

Main Results:

• Early protein subunit vaccines were ineffective, highlighting the need for comprehensive immune responses (antibody and T-cell).
• Viral vector trials targeting T-cell responses alone were insufficient.
• The 2009 RV144 trial demonstrated partial protection, influencing subsequent research to explore complex immune responses and combination technologies.

Conclusions:

• Despite setbacks, extensive research has significantly contributed to HIV vaccine development.
• Ongoing efforts continue to advance understanding of HIV and refine vaccine strategies.
• Novel technologies are being employed to achieve robust, long-lasting immunity against HIV infection.